Protection against influenza a virus challenge with M2e-displaying filamentous Escherichia coli phages

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Deng, Lei ^a,b   Ibañez, Lorena Itatí ^a,b,d   Van Den Bossche, Veronique ^a,b,e   Roose, Kenny ^a,b   Youssef, Sameh A ^c   De Bruin, Alain ^c   Fiers, Walter ^a,b   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COAT PROTEIN; IMMUNOGLOBULIN G; MATRIX PROTEIN 2 VACCINE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; CAPSID PROTEIN; HYBRID PROTEIN; INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVIAN INFLUENZA VIRUS; BACTERIAL CELL; BACTERIOPHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ESCHERICHIA COLI; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NONHUMAN; VIRUS TITRATION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CHEMISTRY; COLIPHAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; VIRUS REPLICATION;

AVES; ESCHERICHIA COLI; FILAMENTOUS BACTERIOPHAGE; HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS; MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; COLIPHAGES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 84929334609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126650     Document Type: Article

References (62)

1. Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine. 2012; 30(23):3459-62. Epub 2012/03/27. doi: S0264-410X (12)00382-9 [pii]. doi: 10.1016/j.vaccine.2012.03.019 PMID: 22446636.
2. der Heiden MA, Kopke K, Buda S, Buchholz U, Haas W. Estimates of excess medically attended acute respiratory infections in periods of seasonal and pandemic influenza in Germany from 2001/02 to 2010/11. PLoS One. 2013; 8(7):e64593. Epub 2013/07/23. doi: 10.1371/journal.pone.0064593 PONE-D-13- 00304 [pii]. PMID: 23874380; PubMed Central PMCID: PMC3712969.
3. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007;(2:) :CD001269. Epub 2007/04/20. doi: 10.1002/14651858.CD001269.pub3 PMID: 17443504.
4. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;(2:) :CD004879. Epub 2008/04/22. doi: 10.1002/14651858.CD004879.pub3 PMID: 18425905.
5. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;(2:) :CD004876. Epub 2010/02/19. doi: 10.1002/14651858.CD004876.pub3 PMID: 20166072.
6. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013; 31(50):6030-3. Epub 2013/10/08. doi: S0264-410X(13)01339-X [pii] doi: 10.1016/j.vaccine.2013.09.063 PMID: 24095882.
7. Stohr K. The global agenda on influenza surveillance and control. Vaccine. 2003; 21(16):1744-8. Epub 2003/04/11. doi: S0264410X03000653 [pii]. PMID: 12686087.
8. Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003; 21(16):1776-9. Epub 2003/04/11. doi: S0264410X03000719 [pii]. PMID: 12686093.
9. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011; 8(1):e1000388. Epub 2011/ 03/08. doi: 10.1371/journal.pmed.1000388 PMID: 21379316; PubMed Central PMCID: PMC3019108.
10. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med. 2013; 5 (185):185ra68. Epub 2013/05/17. doi: 5/185/185ra68 [pii] doi: 10.1126/scitranslmed.3006368 PMID: 23677594.
11. Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J Biol Chem. 2006; 281 (14):8997-9000. Epub 2006/01/13. doi: R500020200 [pii] doi: 10.1074/jbc.R500020200 PMID: 16407184.
12. Beale R, Wise H, Stuart A, Ravenhill BJ, Digard P, Randow F. A LC3-interacting motif in the influenza A virus M2 protein is required to subvert autophagy and maintain virion stability. Cell Host Microbe. 2014; 15(2):239-47. Epub 2014/02/18. doi: S1931-3128(14)00029-8 [pii] doi: 10.1016/j.chom.2014.01.006 PMID: 24528869; PubMed Central PMCID: PMC3991421.
13. Zhirnov OP, Klenk HD. Influenza A virus proteins NS1 and hemagglutinin along with M2 are involved in stimulation of autophagy in infected cells. J Virol. 2013; 87(24):13107-14. Epub 2013/09/13. doi: JVI.02148-13 [pii] doi: 10.1128/JVI.02148-13 PMID: 24027311; PubMed Central PMCID: PMC3838240.
14. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010; 11(5):404-10. Epub 2010/04/13. doi: ni.1861 [pii] doi: 10.1038/ni.1861 PMID: 20383149; PubMed Central PMCID: PMC2857582.
15. Rossman JS, Jing X, Leser GP, Lamb RA. Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell. 2010; 142(6):902-13. Epub 2010/09/21. doi: S0092-8674(10)00960-8 [pii] doi: 10.1016/j.cell.2010.08.029 PMID: 20850012; PubMed Central PMCID: PMC3059587.
16. Gannagé M, Dormann D, Albrecht R, Dengjel J, Torossi T, Ramer PC, et al. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe. 2009; 6(4):367-80. Epub 2009/10/20. doi: S1931-3128(09)00314-X [pii] doi: 10.1016/j.chom.2009.09.005 PMID: 19837376; PubMed Central PMCID: PMC2774833.
17. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J. 2006; 3:102. Epub 2006/12/08. doi: 1743-422X-3-102 [pii] doi: 10.1186/1743-422X-3-102 PMID: 17150104; PubMed Central PMCID: PMC1702354.
18. Schotsaert M, Ysenbaert T, Neyt K, Ibanez LI, Bogaert P, Schepens B, et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol. 2013; 6 (2):276-87. Epub 2012/07/19. doi: 10.1038/mi.2012.69 PMID: 22806098.
19. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis. 2014; 209 (7):986-94. Epub 2013/12/12. doi: jit811 [pii] doi: 10.1093/infdis/jit811 PMID: 24325965.
20. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999; 5(10):1157-63. Epub 1999/09/30. doi: 10.1038/13484 PMID: 10502819.
21. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londono-Arcila P, et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine. 2008; 26(51):6503-7. Epub 2008/10/07. doi: S0264-410X(08)01281-4 [pii] doi: 10.1016/j. vaccine.2008.09.038 PMID: 18835315.
22. Eliasson DG, Helgeby A, Schon K, Nygren C, El-Bakkouri K, Fiers W, et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine. 2011; 29(23):3951-61. Epub 2011/04/13. doi: S0264-410X(11)00483-X [pii] doi: 10.1016/j. vaccine.2011.03.090 PMID: 21481325.
23. Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B, et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9):1243-52. Epub 2008/02/05. doi: S0264-410X(07)01495-8 [pii] doi: 10.1016/j.vaccine.2007.12.027 PMID: 18243429.
24. De Filette M, Ysenbaert T, Roose K, Schotsaert M, Roels S, Goossens E, et al. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. J Gen Virol. 2011; 92(Pt 2):301-6. Epub 2010/10/23. doi: vir.0.027086-0 [pii] doi: 10.1099/vir.0. 027086-0 PMID: 20965983.
25. Reese KA, Lupfer C, Johnson RC, Mitev GM, Mullen VM, Geller BL, et al. A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens. Vet Med Int. 2013; 2013:316926. Epub 2013/06/15. doi: 10. 1155/2013/316926 PMID: 23766929; PubMed Central PMCID: PMC3674685.
26. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011; 29 (32):5145-52. Epub 2011/06/01. doi: 10.1016/j.vaccine.2011.05.041 PMID: 21624416.
27. Wang BZ, Gill HS, He C, Ou C, Wang L, Wang YC, et al. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release. 2014; 178:1-7. Epub 2014/01/15. doi: S0168-3659(14)00019-4 [pii] doi: 10.1016/j.jconrel.2014.01.002 PMID: 24417966; PubMed Central PMCID: PMC3951682.
28. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine. 2003; 21(19-20):2616-26. Epub 2003/05/15. doi: S0264410X03000409 [pii]. PMID: 12744898.
29. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, et al. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS One. 2012; 7(9):e45765. Epub 2012/10/03. doi: 10.1371/journal.pone.0045765 PMID: 23029232; PubMed Central PMCID: PMC3454340.
30. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. European journal of immunology. 2008; 38(1):114-26. Epub 2007/12/18. doi: 10.1002/ eji.200636959 PMID: 18081037.
31. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007; 13(3):426-35. Epub 2007/06/08. doi: 10.3201/eid1303.061125 PMID: 17552096; PubMed Central PMCID: PMC2725899.
32. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 2004; 22(23-24):2993-3003. Epub 2004/08/07. doi: 10.1016/j.vaccine.2004.02.021S0264410X04001835 [pii]. PMID: 15297047.
33. Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J Virol. 1985; 56(2):502-11. Epub 1985/11/01. PMID: 3840537; PubMed Central PMCID: PMC252606.
34. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172 (9):5598-605. Epub 2004/04/22. PMID: 15100303.
35. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011; 186(2):1022-31. Epub 2010/12/21. doi: 10.4049/jimmunol.0902147 PMID: 21169548.
36. Azzazy HM, Highsmith WE Jr., Phage display technology: clinical applications and recent innovations. Clin Biochem. 2002; 35(6):425-45. Epub 2002/11/05. doi: S0009912002003430 [pii]. PMID: 12413604.
37. Prisco A, De Berardinis P. Filamentous bacteriophage fd as an antigen delivery system in vaccination. Int J Mol Sci. 2012; 13(4):5179-94. Epub 2012/05/19. doi: 10.3390/ijms13045179ijms-13-05179 [pii]. PMID: 22606037; PubMed Central PMCID: PMC3344273.
38. Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci. 2004; 24(1):105-13. Epub 2004/08/18. doi: JMN:24:1:105 [pii] doi: 10.1385/ JMN:24:1:105 PMID: 15314258.
39. Solomon B. Filamentous bacteriophage as a novel therapeutic tool for Alzheimer's disease treatment. J Alzheimers Dis. 2008; 15(2):193-8. Epub 2008/10/28. PMID: 18953108.
40. Schagger H. Tricine-SDS-PAGE. Nat Protoc. 2006; 1(1):16-22. Epub 2007/04/05. doi: nprot.2006.4 [pii] doi: 10.1038/nprot.2006.4 PMID: 17406207.
41. Ibanez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PloS one. 2013; 8(3):e59081. doi: 10.1371/journal.pone.0059081 PMID: 23527091; PubMed Central PMCID: PMC3601086.
42. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938; 27:493-7.
43. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A. 2000; 97(21):11455-9. Epub 2000/10/12. doi: 10. 1073/pnas.97.21.1145597/21/11455 [pii]. PMID: 11027345; PubMed Central PMCID: PMC17221.
44. Smith GP, Petrenko VA. Phage Display. Chem Rev. 1997; 97(2):391-410. Epub 1997/04/01. doi: cr960065d [pii]. PMID: 11848876.
45. van Houten NE, Henry KA, Smith GP, Scott JK. Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine. 2010; 28(10):2174-85. Epub 2010/01/09. doi: S0264-410X(09)01976-8 [pii] doi: 10.1016/j.vaccine.2009.12.059 PMID: 20056188; PubMed Central PMCID: PMC2830289.
46. Roose K, Fiers W, Saelens X. Pandemic preparedness: toward a universal influenza vaccine. Drug news & perspectives. 2009; 22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451 PMID: 19330167.
47. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Journal of virology. 1988; 62(8):2762-72. Epub 1988/08/01. PMID: 2455818; PubMed Central PMCID: PMC253710.
48. Zebedee SL, Lamb RA. Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86(3):1061-5. Epub 1989/02/01. PMID: 2915973; PubMed Central PMCID: PMC286621.
49. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. Journal of virology. 2005; 79(11):6644-54. Epub 2005/05/14. doi: 10.1128/JVI.79.11.6644-6654.2005 PMID: 15890902; PubMed Central PMCID: PMC1112148.
50. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem. 2008; 283(17):11382-7. Epub 2008/02/07. doi: M800650200 [pii] doi: 10.1074/jbc.M800650200 PMID: 18252707; PubMed Central PMCID: PMC2431085.
51. Paschke M. Phage display systems and their applications. Appl Microbiol Biotechnol. 2006; 70(1):2-11. Epub 2005/12/21. doi: 10.1007/s00253-005-0270-9 PMID: 16365766.
52. Malik P, Terry TD, Gowda LR, Langara A, Petukhov SA, Symmons MF, et al. Role of capsid structure and membrane protein processing in determining the size and copy number of peptides displayed on the major coat protein of filamentous bacteriophage. J Mol Biol. 1996; 260(1):9-21. Epub 1996/07/05. doi: S0022-2836(96)90378-2 [pii] doi: 10.1006/jmbi.1996.0378 PMID: 8676395.
53. Endemann H, Model P. Location of filamentous phage minor coat proteins in phage and in infected cells. J Mol Biol. 1995; 250(4):496-506. Epub 1995/07/21. doi: S0022283685703932 [pii]. PMID: 7616570.
54. Liu W, Zou P, Chen YH. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett. 2004; 93(2-3):131-6. Epub 2004/05/26. doi: 10.1016/j.imlet.2004.03.003S0165247804000616 [pii]. PMID: 15158608.
55. Pejoski D, Zeng W, Rockman S, Brown LE, Jackson DC. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol. 2010; 88(5):605-11. Epub 2010/02/24. doi: 10.1038/icb.2010.15 PMID: 20177411.
56. Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G, et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One. 2009; 4(5):e5538. Epub 2009/05/15. doi: 10.1371/journal.pone.0005538 PMID: 19440239; PubMed Central PMCID: PMC2678248.
57. Pommerenke C, Wilk E, Srivastava B, Schulze A, Novoselova N, Geffers R, et al. Global transcriptome analysis in influenza-infected mouse lungs reveals the kinetics of innate and adaptive host immune responses. PloS one. 2012; 7(7):e41169. doi: 10.1371/journal.pone.0041169 PMID: 22815957; PubMed Central PMCID: PMC3398930.
58. Herve PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N, et al. A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. Journal of virology. 2014; 88(1):325-38. Epub 2013/10/25. doi: 10.1128/JVI.01141-13 PMID: 24155388; PubMed Central PMCID: PMC3911713.
59. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. Journal of virology. 1990; 64 (3):1375-7. Epub 1990/03/01. PMID: 2304147; PubMed Central PMCID: PMC249260.
60. Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107 (28):12658-63. Epub 2010/07/10. doi: 10.1073/pnas.0911806107 PMID: 20615945; PubMed Central PMCID: PMC2906546.
61. Meola A, Delmastro P, Monaci P, Luzzago A, Nicosia A, Felici F, et al. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J Immunol. 1995; 154(7):3162-72. Epub 1995/04/01. PMID: 7534789.
62. Bastien N, Trudel M, Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology. 1997; 234(1):118-22. Epub 1997/07/21. doi: 10.1006/viro.1997.8632 PMID: 9234952.